Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin

Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation

(2012) Rickard Ljung et al.   ACTA ONCOLOGICA

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

(2012) P. Blin et al.   DIABETOLOGIA

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2

(2012) Cécile Pierre-Eugene et al.   PLoS One

Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation

(2011) Rickard Ljung et al.   ACTA ONCOLOGICA

Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A retrospective cohort study of older Medicare patients

(2011) N. E. Morden et al.   DIABETES CARE

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data

(2011) T. P. van Staa et al.   DIABETOLOGIA

Long-term effects of insulin glargine on the risk of breast cancer

(2011) S. Suissa et al.   DIABETOLOGIA

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study

(2011) R. Ruiter et al.   DIABETOLOGIA

Nonexperimental Comparative Effectiveness Research Using Linked Healthcare Databases

(2011) Til Stürmer et al.   EPIDEMIOLOGY

Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study

(2011) Chia-Hsuin Chang et al.   PLoS One

Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation Study

(2010) T. Sturmer et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients

(2010) E. Mannucci et al.   DIABETES CARE

Diabetes and Cancer: A consensus report

(2010) E. Giovannucci et al.   DIABETES CARE

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites

(2010) Mark R. Sommerfeld et al.   PLoS One

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

(2009) P. D. Home et al.   DIABETOLOGIA

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

(2009) J. Rosenstock et al.   DIABETOLOGIA

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

(2009) J. M. Jonasson et al.   DIABETOLOGIA

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

(2009) H. M. Colhoun et al.   DIABETOLOGIA

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

(2009) C. J. Currie et al.   DIABETOLOGIA

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

(2009) L. G. Hemkens et al.   DIABETOLOGIA

Diabetes and cancer

(2009) Paolo Vigneri et al.   ENDOCRINE-RELATED CANCER